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Estrogen deficiency is one of the main causes of age-associated diseases in the cardiovascular system. Female Wistar rats were
divided into four experimental groups: pharmacologically ovariectomized, surgically ovariectomized, and 24-month-old intact
aging animals were compared with a control group. The activity and expression of heme oxygenases (HO) in the cardiac left
ventricle, the concentrations of cardiac interleukin-6 (IL-6) and tumor necrosis factor-𝛼 (TNF-𝛼), the myeloperoxidase (MPO)
activity in the cardiac left ventricle, and the effects of heme oxygenase blockade (by 24-hour and 1-hour pretreatment with tin-
protoporphyrin IX, SnPP) on the epinephrine and phentolamine-induced electrocardiogram ST segment changes in vivo were
investigated. The cardiac HO activity and the expression of HO-1 and HO-2 were significantly decreased in the aged rats and
after ovariectomy. Estrogen depletion was accompanied by significant increases in the expression of IL-6 and TNF-𝛼. The aged and
ovariectomized animals exhibited a significantly elevatedMPO activity and a significant ST segment depression. After pretreatment
with SnPP augmented ST segment changes were determined. These findings demonstrate that the sensitivity to cardiac ischemia
in estrogen depletion models is associated with suppression of the activity and expression of the HO system and increases in the
secretion of proinflammatory cytokines and biomarkers.
1. Introduction
Many epidemiological studies have suggested the involve-
ment of free radicals and oxidative stress in aging and certain
age-related processes that often accompany the menopause
[1–3]. An increased level of production of reactive oxygen
species (ROS) is considered to be one of the major causes
of age-related morbidity (e.g., coronary artery and general
cardiovascular dysfunctions) [4]. Estrogen protects women
against cardiovascular diseases and seems to play amajor role
in sex-related differences in hypertension in experimental
models [5]. Antioxidant properties may also be involved
since estradiol can reduce the expression of nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase subunits
and increase the expression of superoxide dismutase [6, 7].
Estradiol protects endothelial cells against damage by
oxidants and induces the generation of endothelial derived
vasodilators, such as nitric oxide (NO) [8]. Recent data indi-
cate that another system associatedwith cardioprotection, the
heme oxygenase (HO) system, is also affected by estrogen
[9]. HO-1 can catalyze the oxidative degradation of heme to
yield equimolar amounts of biliverdin, free iron, and carbon
monoxide (CO). Biliverdin is metabolized to bilirubin by
biliverdin reductase. Among the products of HO-1, bilirubin
and biliverdin are the most potent endogenous scavengers
of ROS and CO exerts antiapoptotic and anti-inflammatory
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effects through the induction of soluble guanyl cyclase. CO
additionally suppresses the production of proinflammatory
cytokines, such as tumor necrosis factor-alpha (TNF-𝛼) [10].
The aim of our work was to investigate the effects of
estrogen depletion on the activation and expression of HO in
the cardiovascular system and on inflammatory biomarkers,
such as the levels of TNF-𝛼 and interleukin-6 (IL-6) and
the activity of myeloperoxidase (MPO) in experimental
menopause.
2. Methods
2.1. Experimental Groups of Animals. All experimental pro-
cedures were performed in accordance with the standards
of the European Community guidelines on the care and
use of laboratory animals and had been approved by the
Institutional Ethics Committee.
Female Wistar rats were divided into four groups: 4-
month-old sham-operated controls, 4-month-old pharma-
cologically ovariectomized (POVX) animals, 4-month-old
surgically ovariectomized (OVX) animals, and 24-month-old
ovary-intact (aged) animals.
Ovariectomy surgery was performed on anesthetized
animals via a small ventral abdominal midline incision. The
ovaries were clamped bilaterally and removed. The uterine
horns were tied and the uterus was left intact.The abdominal
wall was then sutured. In the sham procedure, the animals
were anesthetized and the abdominal wall was opened but the
ovaries were not removed. The ovaries were exteriorized to
create a similar degree of stress. Other groups of female rats
received treatment with 750𝜇g/kg triptorelin (Decapeptyl
depot, Ferring, Germany) i.m. every 4 weeks in order to
achieve pharmacological ovariectomy [11]. After a 6-week
resting period to verify the surgically or pharmacologically
inducedmenopause and to ensure that all animals were killed
at the same stage of the estrus phase (all the control rats
were in the proestrus phase) via Giemsa staining method
we checked the estrogen level with estrogen quantitative
enzyme-linked immunosorbent assay according to the man-
ufacturer’s directions (Quantikine rat Estrogen Elisa kit, R&D
Systems Inc.) [12].
2.2. Cardiac Left Ventricle HO Activity. The cardiac left
ventricle (LV) tissues were homogenized (Ultra Turrax
T25; 13.500min−1; 2 × 30 s) in ice-cold 10.0mM N-2-
hydroxyethylpiperazine-N󸀠-2-ethanesulfonic acid, 32.0mM
sucrose, 1.0mM dithiotreitol, 0.10mM ethylenediaminete-
traacetic acid disodium salt dihydrate (EDTA), 10.0 𝜇g/mL
trypsin inhibitor, 10.0 𝜇g/mL leupeptin, and 2.0 𝜇g/mL apro-
tinin; pH 7.4. The supernatant was collected by centrifu-
gation at 15000 g for 20min at 4∘C. The reaction mixture
contained the following compounds in a final volume of
1.50mL: 2.0mM glucose-6-phosphate, 0.14U/mL glucose-6-
phosphate dehydrogenase, 15.0 𝜇M hemin, 120.0𝜇g/mL rat
liver cytosol as a source of biliverdin reductase, 2.0mM
MgCl
2
× 6H
2
O, 100.0mM KH
2
PO
4
, and 150.0 𝜇L of super-
natant. To start the reaction 100.0𝜇L the reduced form of 𝛽-
nicotinamide adenine dinucleotide phosphate, reduced form
(150.0 𝜇M), was added to the samples and they were then
incubated in the dark at 37∘C for 60min. The reaction was
stopped by placing the samples on ice. The bilirubin formed
was calculated from the difference between the optical den-
sities obtained at 464 and 530 nm. Bilirubin solution was
used as standard (58.47𝜇g/mL; 10.0 𝜇M). Protein content was
determined by spectrophotometric assay (Bio-Rad Protein
Assay).
One unit of HO activity was defined as the amount of
bilirubin (nmol) produced per hour per mg protein.
2.3. Cardiac LV HO-1 and HO-2 Expression. The expression
of HO-1 and HO-2 enzymes was determined byWestern blot
analysis. The cardiac LV tissues were homogenized (Ultra
Turrax T25; 13.500min−1; 2 × 30 s) in ice-cold Tris-mannitol
buffer (2.0mMTris 7–9, 50.0mMmannitol, 100.0𝜇Mphenyl
methyl sulfonyl fluoride, 2.0 𝜇M leupeptin, 0.50mU/mL
aprotinin, and 0.50% Triton X-100). Homogenizates were
centrifuged at 12000 g for 20min at 4∘C. Protein content
was measured by spectrophotometric assay (Bio-Rad Protein
Assay).
Aliquots of 25.0 𝜇g of total cellular protein were dena-
tured by mixing and boiling with 20.0mM Tris 7–9,
3.0mM EDTA, 2.0% sodium dodecyl sulfate, 10.0% 𝛽-
mercaptoethanol, and 20.0% glycerol. The samples were
electrophoresed (100V, 50mA) on 10.0% polyacrylamide gel
and transferred (100V, 100mA, 2 h) to a nitrocellulose mem-
brane (Amersham, Pharmacia Biotech., Buckinghamshire,
UK). Equal protein loading was determined by staining the
blot with 0.10% Ponceau red in 5.0% acetic acid. Two h
after blocking with PBS (pH 7.4), 0.25% Tween 20, and
5.0% fat-free dried milk, the membrane was probed for
2 h with mouse anti-HO-1 monoclonal antibody (1/10.000;
StressGen Biotechnologies Corp., Victoria, Canada) or anti-
HO-2 monoclonal antibody (1/1000; StressGen Biotechnolo-
gies Corp., Victoria, Canada) at room temperature, washed
3 times with PBS-Tween 20, and then incubated for 1 h
with horseradish peroxidase-conjugated bovine anti-mouse
antibody (1/2000; Santa Cruz Biotechnology Inc., Santa Cruz,
CA, USA) at room temperature. Membranes (Hybond ECL
Nitrocellulose membrane, Amersham, Pharmacia Biotech.,
Buckinghamshire, UK)were developed by using an enhanced
chemiluminescence system (ECL+Plus, Amersham Pharma-
cia Biotech., Buckinghamshire, UK) and exposed to Hyper-
film (Biomax light-1, Eastman Kodak Comp., Rochester,
NY, USA). Films were analyzed by using ImageQuant
Software (Amersham Pharmacia Biotech., Buckinghamshire,
UK) after scanning with GelAnalyst 3.01 Software (Iconix,
Toronto, Canada).
2.4. Measurement of Cardiac LV IL-6 and TNF-𝛼 Concen-
trations. The IL-6 and TNF-𝛼 levels were determined by
means of quantitative enzyme-linked immunosorbent assays
according to the manufacturer’s directions (Quantikine rat
IL-6 and TNF-alpha Elisa kit, R&D Systems Inc.). Optical
density was measured at 450 nm (Benchmark Microplate
reader; Bio-Rad). IL-6 and TNF-𝛼 were expressed as pg/mg
protein.
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2.5. Cardiac LV MPO Activity. The cardiac LV tissues were
homogenized (Ultra Turrax, T25, 13 500 r.p.m., twice for 30 s)
in ice-cold phosphate buffer (50mM, pH 6.0), freeze-thawed
three times, and then centrifuged twice (each time at 15 000 g
for 15min at 4∘C). A 12𝜇L aliquot of the supernatant was
next mixed with 280𝜇L of phosphate buffer (50mM, pH
6) containing 0.167mgmL−1 of O-dianisidine dihydrochlo-
ride and the reaction was started with 10 𝜇L of 0.03%
hydrogen peroxide and assayed spectrophotometrically at
490 nm (Benchmark Microplate reader; Bio-Rad, Budapest,
Hungary) after 90 s of shaking. MPO activity was expressed
as mU/mg protein.
2.6. Experimental Angina Provoked by Epinephrine Plus Phen-
tolamine. The standard limb lead II of the surface electro-
cardiogram (ECG) was recorded by the HAEMOSYS system
(Experimetria Ltd., Budapest, Hungary). The change in the
ST segment was measured and used as the index of angina
severity. The mean ECG voltage 13ms after the peak of the S
wave was defined as the value of the ST segment, as described
previously [13, 14]. The difference in the amplitude of the ST
segment after and before the administration of the angina-
provoking agents was calculated and expressed as the depres-
sion of the ST segment in mV. In the epinephrine plus phen-
tolamine model, a single dose of epinephrine (10.0 𝜇g/kg)
and 30 s later the 𝛼-adrenoceptor antagonist phentolamine
(15.0mg/kg) were administered into the tail vein of the rat.
Each agent was dissolved in 0.20mL of physiological saline
and injected over 2 s. The ECG was recorded simultaneously.
To investigate the effects of HO enzyme activity inhibition on
ST segment changes tin-protoporphyrin IX (30.0 𝜇mol/kg,
s.c., pH 7.4) was administrated 24 h and 1 h before treatment.
2.7. Chemicals. Apart from epinephrine (Tonogen, Richter
Gedeon, Hungary), Phentolamine (Regitin, P; Ciba-Geigy,
Switzerland), SnPP (Frontier Scientific Europe, United King-
dom), and triptorelin (Decapeptyl depot, Ferring, Germany),
all chemicals were from Sigma Aldrich Company.
2.8. Statistical Analysis. Data are reported as means ± S.E.M.
of the results from at least 3 independent experiments.
Western blots are shown as representative photographs of
three independent experiments. Statistical significance was
assessed by ANOVA; 𝑃 < 0.05 was taken as significant.
3. Results
3.1. Cardiac LV HO Activity. As shown in Figure 1, the
activity of HO was determined by measurement of bilirubin
formation in the cardiac LV. We found that HO activity was
significantly (∗𝑃 < 0.05) decreased in the ovariectomized
(POVX: 0.68 ± 0.1 nmol bilirubin/h/mg protein, 𝑛 = 12;
OVX: 0.73 ± 0.1 nmol bilirubin/h/mg protein, 𝑛 = 11) and
aged (0.61 ± 0.13 nmol bilirubin/h/mg protein, 𝑛 = 11)
animals compared to the control group (1.59 ± 0.2 nmol
bilirubin/h/mg protein, 𝑛 = 11).
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Figure 1: Heme oxygenase activity (HO; expressed as nmol/bili-
rubin/h/mg protein) in the cardiac left ventricle of control, ovariec-
tomized (pharmacologically POVX and surgically OVX), and aged
rats. A significant decrease was observed in the HO activity of the
ovariectomized and aged rats as compared with the controls. Data
are expressed as means ± S.E.M., 𝑛 = 11-12. Statistical significance:
∗
𝑃 < 0.05 relative to the control (sham-operated) group.
3.2. Cardiac LV HO-1 and HO-2 Expression. HO-1 and HO-
2 protein were determined by Western blot techniques. Data
are shown in Figure 2. In both the POVX and OVX rats, the
cardiac expression of HO-1 (POVX: 32.87 ± 3.92%, 𝑛 = 10;
OVX: 32.92 ± 3.1%, 𝑛 = 10) and HO-2 (POVX: 36.4 ± 5.3%,
𝑛 = 10; OVX: 35.8 ± 5.22%, 𝑛 = 10) was significantly (∗𝑃 <
0.05) lower than in the controls (HO-1: 84.33 ± 4.3%, 𝑛 = 10;
HO-2: 89.29±2.6%, 𝑛 = 10). Aging was also accompanied by
a significantly (∗𝑃 < 0.05) reduced cardiac expression of HO-
1 (32.62 ± 2.89%, 𝑛 = 10) and HO-2 protein (37.95 ± 2.42%,
𝑛 = 10) relative to the control group.
3.3. Cardiac LV IL-6 and TNF-𝛼 Concentrations. The levels
of the proinflammatory cytokines IL-6 and TNF-𝛼 were
significantly (∗𝑃 < 0.05) elevated during aging and after
ovariectomy in both the POVX and OVX groups in com-
parison with the control animals. Additionally, the increase
in cardiac LV IL-6 concentration was more marked in the
aged group than in the ovariectomized and control animals
(IL-6 concentration in the aged group: 89.434 ± 5.817 pg/mg
protein, 𝑛 = 8; in the POVX group: 62.503 ± 7.339, 𝑛 = 9;
in the OVX group: 61.403 ± 5.512 pg/mg protein, 𝑛 = 8;
and in the controls: 41.797 ± 4.673 pg/mg protein, 𝑛 = 9;
TNF-𝛼 concentration in the aged group: 6.622 ± 0.657 pg/mg
protein, 𝑛 = 8; in the POVX group: 5.648 ± 0.598 pg/mg
protein, 𝑛 = 8; in the OVX group: 6.015 ± 0.415 pg/mg
protein, 𝑛 = 6; and in the controls: 3.520 ± 0.502 pg/mg
protein, 𝑛 = 7). The results are presented in Figure 3.
3.4. Cardiac LV MPO Activity. The activity of MPO was
significantly (∗𝑃 < 0.05) higher in the cardiac LV of the
POVX (71.0 ± 8.34mU/mg protein, 𝑛 = 7), OVX (75.0 ±
8.42mU/mg protein, 𝑛 = 8), and aged (76.0 ± 4.192mU/mg
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Figure 2: Detection of heme oxygenase expression (HO-1 and HO-2; expressed as %) by Western blot analysis in the cardiac left ventricle of
control, ovariectomized (pharmacologically POVX and surgically OVX), and aged rats. (a) Heme oxygenase-1 enzyme (HO-1; expressed as %,
100% being the maximal expression) in the cardiac left ventricle of control, ovariectomized (pharmacologically POVX and surgically OVX),
and aged rats with densitometric assessment. There was a significant decrease in HO-1 expression in the ovariectomized and aged groups.
Data are expressed as means ± S.E.M., 𝑛 = 10. Statistical significance: ∗𝑃 < 0.05 relative to the control (sham-operated) group. (b) Heme
oxygenase-2 expression (HO-2; expressed as %, 100% being the maximal expression) in the cardiac left ventricle of control, ovariectomized
(pharmacologically POVXand surgicallyOVX), and aged rats, with densitometric assessment.TheHO-2 expression proved to be significantly
decreased in the ovariectomized and aged rats. Data are expressed as means ± S.E.M., 𝑛 = 10. Statistical significance: ∗𝑃 < 0.05 relative to the
control (sham-operated) group.
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Figure 3: The levels of the proinflammatory cytokines interleukin- (IL-) 6 and tumor necrosis factor-alpha (TNF-𝛼) in control,
ovariectomized (pharmacologically POVX and surgically OVX), and aged rats. (a) Cardiac LV IL-6 level (expressed as pg/mg protein) in
control, ovariectomized (POVX, OVX), and aged rats. The IL-6 level was significantly increased in the ovariectomized rats as compared with
the control. The aged group exhibited a more significant increase than that of the ovariectomized group. Data are shown as means ± S.E.M.,
𝑛 = 8–10. Statistical significance: ∗𝑃 < 0.05 relative to the control group, and +𝑃 < 0.05 relative to the ovariectomized animals. (b) Cardiac
LV tumor necrosis factor-alpha concentration (TNF-𝛼; expressed as pg/mg protein) in control, ovariectomized (POVX, OVX), and aged rats.
The TNF-𝛼 concentration was significantly higher in the ovariectomized and aged animals. Data are expressed as means ± S.E.M., 𝑛 = 6–8.
Statistical significance: ∗𝑃 < 0.05 relative to the control (sham-operated) group.
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Figure 4: Myeloperoxidase activity (MPO; expressed as mU/mg
protein) in the myocardium of control, ovariectomized (pharmaco-
logically POVX, surgically OVX), and aged rats. The MPO enzyme
activity was significantly enhanced in the ovariectomized and aged
animals. Results are shown as means ± S.E.M., 𝑛 = 7-8. Statistical
significance: ∗𝑃 < 0.05 relative to the control (sham-operated)
group.
protein; 𝑛 = 8) groups as compared to control ones (59.00 ±
4.367mU/mg protein, 𝑛 = 8). The data are to be seen in
Figure 4.
3.5. Effects of Inhibition of HO Activity on Cardiac Ischemia.
The administration of phentolamine caused a significant
(∗𝑃 < 0.05) ST segment depression 30 s following
epinephrine administration in the POVX (−0.15 ± 0.015mV,
𝑛 = 13), OVX (−0.14 ± 0.0389mV, 𝑛 = 13), and aged
(−0.19 ± 0.023mV, 𝑛 = 13) rats. In the ovary-intact sham-
operated females, the ST segment depression was −0.0116 ±
0.028mV, 𝑛 = 4. Pretreatment with the HO inhibitor SnPP
(30.0 𝜇mol/kg, s.c. pretreatment 24 h and 1 h prior to the
measurement) caused an ST depression in the sham-operated
animals (−0.19 ± 0.02mV, 𝑛 = 11), and significantly (#𝑃 <
0.05) augmented the ST depression in the POVX (−0.31 ±
0.04mV, 𝑛 = 3), OVX (−0.34 ± 0.035mV, 𝑛 = 11), and aged
(−0.29 ± 0.056mV, 𝑛 = 11) groups. The data are depicted in
Figure 5.
4. Discussion
We conclude that pharmacological treatment with an aro-
matase inhibitor triptorelin (POVX) and surgical ovariec-
tomy (OVX) are valuable conditions for effective estrogen
studies.
The female cardiovascular system is influenced by
changes in the endocrine system. During the menopausal
transition, dramatic hormonal changes such as declining
levels of estrogen and rising levels of gonadotropins may
affect the cardiovascular system. Estrogen deficiency induces
an imbalance between enhanced ROS production and
inadequate antioxidant activity. The decline in ovarian
function accompanying the menopause, OVX, and POVX
contributes to the induction of proinflammatory cytokines
such as TNF-𝛼 and IL-6. Estrogen is a well-known regulator
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Figure 5: The effects of HO activity inhibition by tin-
protoporphyrin-IX (SnPP) on the ST segment (measured in
a lead II standard surface ECG, expressed in mV) following
intravenous injection of epinephrine (10.0𝜇g/kg) and 30 s later
phentolamine (15.0mg/kg).The columns show significant decreases
in the ST segment of ovariectomized and aged animals without
SnPP treatment. SnPP pretreatment (30.0 𝜇mol/kg, s.c., pH 7.4,
24 h and 1 h pretreatment) caused a significant ST depression in the
sham-operated control animals. Following ovariectomy (POVX and
OVX), or in aged rats, the SnPP treatment induced a more marked
significant decrease in ST as compared with the control. Results
are shown as means ± S.E.M., 𝑛 = 11–13. Statistical significance:
∗
𝑃 < 0.05 relative to the ovary-intact sham-operated control
group; #𝑃 < 0.05 a significant difference between groups with
and without SnPP pretreatment; a𝑃 < 0.05 a significant difference
between the data for the ovariectomized and aged groups after
SnPP pretreatment and those for the controls.
of inflammation. Cardiovascular and immune system
abnormalities have been reported in females with estrogen
deficiency, exerting a number of known anti-inflammatory
effects through a variety of different mechanisms, both
genomic and nongenomic. The anti-inflammatory role
ranges from generating NO and regulating leukocyte
recruitment to reducing oxidative stress and promoting cell
survival.These effects contribute to dampening inflammation
in the vascular system. Estrogen deficiency has been shown
to upregulate TNF-𝛼 levels in aged animals with deleterious
effects on vascular function. Such effects are largely
mediated through increased oxidative stress and can be
reversed through exogenous estrogen, a TNF-𝛼 inhibitor,
or antioxidants [15]. Sex hormones are known modifiers of
the inflammatory response to injury, an important aspect of
myocardial dysfunction and cardiomyocyte death following
ischemia. Hamilton et al. in their experiments showed that
the overall effect of OVX on myocardial gene expression was
increased expression of genes involved in the inflammatory
response. OVX increased IL-6 receptor, TNF-𝛼, complement
8, and SOCS2 and SOCS3 expression [16]. During aging and
after ovariectomy, estrogen deficiency is able to stimulate
the spontaneous secretion of such proinflammatory
cytokines. Along with the effects of cytokines, the MPO
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activity is determined as an inflammatory biomarker.
Inflammation and oxidative stress are associated with
atherosclerosis and cardiovascular disease. Conversely,
inflammation also triggers vascular remodeling, aggravates
vessel injury, and exacerbates the processes of hypertension
and atherosclerosis [17]. MPO plays a significant role
in the development of the atherosclerotic lesion and
renders the plaques unstable, which is associated with
the aging mechanism and cardiovascular disease [18].
Similar results demonstrate the role of HO-1 in HO-1
knockout mice, in which the HO-1 deficiency leads to an
increased production of proinflammatory cytokines [9]
while HO-1 upregulation successfully slows the processes
of hypertension and myocardial infarction [19]. Preclinical
and clinical evidence clearly suggest that the progression
of atherosclerosis is associated with inflammation. The
CO derived from HO has been demonstrated to protect
against TNF-𝛼-induced apoptosis [20]. Aging leads to
significantly increased levels of the proinflammatory
cytokines in the liver of aged female rats as compared with
young controls. Hence, the diminished activity of the HO
system contributes to increased oxidative stress [21]. Ross
and Howlett demonstrated that the ventricular myocytes
from young female rats were more resistant to ischemia and
reperfusion injury than were cells from males, and then
ischemia and reperfusion injury in female myocytes was
exacerbated by aging or by OVX. Advancing age abolishes
the beneficial effects of the female sex on the cell viability
and the contractile function [22]. Our data indicated that
aging and estrogen depletion process abolished the beneficial
effects of the female sex in the myocardium. This suggests
that the cardioprotection of the female sex may decline with
age in response to a reduction in circulating estradiol levels.
Indeed, we found that the removal of estrogen through OVX
or POVX exacerbated the adverse effects of ischemia, which
can be augmented via HO activity inhibition. Our results
indicate that decreases in the expression of HO-1/HO-2
and in the activity of the HO system are important factors
that contribute to the enhanced sensitivity of the OVX or
POVX heart to ischemia. Moreover, we found that aging
and OVX induced diminished HO activity and expression.
Direct vascular effects of estradiol are believed to play a
significant role in the cardioprotectivity of estrogens. These
findings on OVX and POVX female rats may have important
clinical implications. Extensive epidemiological studies
of the morbidity and mortality rates of postmenopausal
women have revealed a significant increase in cardiovascular
mortality as compared with that in women who are still
menstruating. After the menopause, women lose the relative
cardiovascular protection that they had previously enjoyed
over men [23, 24]. Although estrogen has been reported
to protect the cardiovascular system, the mechanisms
involved remain unclear. Estrogen exerts genomic and
nongenomic effects via estrogen receptor-dependent and
receptor-independent mechanisms, to confer protective
effects on the cardiovascular system. Alterations in plasma
concentrations of lipoproteins (decreases in low-density
lipoprotein levels and in oxidized low-density lipoprotein
formation and increases in high-density lipoprotein
levels), hemostatic factors, glucose, insulin, and
endothelium-derived factors (decreases in endothelin
and increases in NO and prostaglandins) and the inhibition
of smooth muscle cell migration and proliferation induced
by various mitogens are thought to contribute to the
vasoprotective effects of estrogen [25]. Of these biological
effects, the antioxidant effects of estrogen may play a critical
role in eliciting vasoprotective effects [26]. Endogenous
and exogenous estrogens have antioxidant potential both
in vitro [27] and ex vivo [28]. An estrogen deficiency in
the menopausal state therefore leads to changes in the
homeostatic environment of the body, for example, a gradual
increase in oxidative stress. A previous report from our
laboratory supports this concept, demonstrating the sexual
dimorphism in HO activity and expression. The present
study demonstrated similar results in that the HO levels in
the hearts of OVX rats were markedly lower than those in
the sham-operated controls. HO has potent cytoprotective
effects that are likely to be mediated by its products, CO,
biliverdin/bilirubin, and free iron, and we were interested in
the role of HO in an estrogen-deficient environment.TheHO
levels proved to be reduced in the aged and ovariectomized
rats, which might result from the downregulation of HO in
the heart tissues. After OVX, a marked reduction in estrogen
synthesis led to decreases in the activity and expression of
HO.
We also found that the cardiac LV levels of IL-6 and
TNF-𝛼 were significantly reduced after ovariectomy and the
menopause. An estrogen deficiency may lead to an increased
activity of MPO.
However, only a small amount of data is available con-
cerning the effects of HO expression in vivo. It emerged
from the current study that an HO activity inhibitor caused
an ST depression in control female rats and augmented the
ST depression in the estrogen-withdrawal model. The data
suggest that the HO activity protects the heart at a fertile age.
This study has also demonstrated that the inhibition of
HO activity in ovariectomized rats significantly increases the
ST depression, implying that HO plays a protective role in the
cardiovascular system. Although a number of studies have
clearly pointed to the vasculoprotective effects of estrogen
in animal models, the targets of estrogen are numerous
and estrogen deficiency affects the cardiovascular system at
different points. In summary, the decreased level and activity
of HO in the hearts of OVX and POVX rats may cause the
development of atherosclerosis after the menopause.
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